---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336685"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2026-08-06T11:04:15+00:00"
generated_at: "2026-08-06T11:06:06.020408+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Korro Bio Q2 net loss $18.9M, cash $137.9M; exchanges 1M shares for pre-funded warrants

## Summary
- Net loss $18.9M for Q2 2026 vs $25.8M in Q2 2025; no collaboration revenue due to Novo Nordisk pause.
- Cash, equivalents and marketable securities $137.9M as of June 30, 2026; runway into H2 2028.
- Exchange agreement: VenRock surrenders 1M shares for pre-funded warrants at $0.001 exercise price, no expiration.
- KRRO-121 on track for first-in-human trial H2 2026; received EMA Orphan Drug Designation for UCDs.
- Nominated KRRO-111 for AATD; preclinical data shows >90% editing and ~95% reduction of Z-AAT aggregates.

## SEC filing metadata
- accession: 0001193125-26-336685
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2026-08-06T11:04:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/0001193125-26-336685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336685
- JSON: https://secwatch.observer/filing/0001193125-26-336685.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.